Evidence map›Paper›PMID 36799965›Full record

ReviewChirurgie (Heidelberg, Germany)2023

[Hereditary medullary thyroid cancer].

V Fendrich, A Zahn

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Chirurgie (Heidelberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

V FendrichKlinik für Endokrine Chirurgie, Schön Klinik Eilbek, Dehnhaide 120, 22081, Hamburg, Deutschland. vfendrich@schoen-kliniken.de.
A ZahnKlinik für Endokrine Chirurgie, Schön Klinik Eilbek, Dehnhaide 120, 22081, Hamburg, Deutschland.
Schön Klinik Hamburg Eilbek · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parafollicular C cells progress via C cell hyperplasia to medullary thyroid cancer (MTC), which can be present even in the first years of life in multiple endocrine neoplasia (MEN) type 2A and 2B patients. Basal calcitonin and carcinoembryonic antigen (CEA) are useful tumor markers for the diagnosis and monitoring. The prognosis depends on the stage when the disease is diagnosed and there is a good genotype-phenotype correlation with the RET proto-oncogene, which can be used for estimation of the risk. The risk-stratified prophylactic thyroidectomy plays a decisive role in the prognosis of known gene mutation carriers.

Indexed as

Carcinoma, MedullaryThyroid NeoplasmsHumansMultiple Endocrine Neoplasia Type 2aProto-Oncogene MasProto-Oncogene Proteins c-retProto-Oncogene MasProto-Oncogene Proteins c-retCalcitoninGenotype-phenotype correlationMEN2Prophylactic thyroidectomyRET proto-oncogene

Identifiers

PMID36799965
OpenAlexW4321163190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.